Today, based on a board resolution, Kissei Pharmaceutical will conduct a treasury stock acquisition via ToSTNeT-3. Up to 1,100,000 shares (2.64% of outstanding shares) will be repurchased for a total exceeding 4,000,000,000 yen, announced on 2026-11-05, with the acquisition dependent on trading results at the close of 08:45 on 2026-11-05.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4547","jir_company_name":"Kissei Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-04","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4547-20261104-03.pdf","jir_short_summary":"Today, based on a board resolution, Kissei Pharmaceutical will conduct a treasury stock acquisition via ToSTNeT-3. Up to 1,100,000 shares (2.64% of outstanding shares) will be repurchased for a total exceeding 4,000,000,000 yen, announced on 2026-11-05, with the acquisition dependent on trading results at the close of 08:45 on 2026-11-05.","jir_summary":"### Key Points of Treasury Stock Acquisition\nKissei Pharmaceutical Co., Ltd. today determined the specific method for acquiring treasury stock based on the board resolution held on May 11, 2026. The market purchase via ToSTNeT-3 will be announced after the close of trading at 08:45 on November 5, 2026. The total number of shares to be acquired is up to 1,100,000 shares (2.64% of outstanding shares), and the total purchase price is up to 4,130,500,000 yen. Depending on market conditions, some or all of the planned acquisitions may not be executed.\n\n### Background and Future Outlook\nThis acquisition is part of capital policy aimed at enhancing shareholder returns and capital efficiency through proactive treasury stock purchases. The acquisition results will be announced on November 5, 2026, and subsequent treasury stock holdings will be disclosed as appropriate. Cumulative past acquisitions amount to 200,000 shares, with a total purchase price of 79,931,500 yen (as of November 4, 2026).","jir_financial_highlights":"Total number of shares to be acquired: 1,100,000 shares (maximum) (Unknown)\nTotal purchase price of shares: 4,130,500,000 yen (maximum) (Unknown)","jir_category":"","jir_hashtags":"#KisseiPharmaceutical, #ShareBuyback","jir_key_figures":"Total number of shares to be acquired: 1,100,000 shares (maximum)\nTotal purchase price of shares: 4,130,500,000 yen (maximum)\nCumulative number of shares acquired (as of 2026\/11\/4): 200,000 shares","jir_meta_title":"Kissei Pharmaceutical Co., Ltd. Announces Treasury Stock Acquisition\uff5cNovember 2026","jir_meta_description":"Kissei Pharmaceutical Co., Ltd. will repurchase treasury stock via ToSTNeT-3, setting an upper limit of 1,100,000 shares and a maximum total of 4,130,500,000 yen. Announcement date and acquisition conditions are provided. Monitor for implications on shareholder returns and capital efficiency.","jir_og_title":"Kissei Pharmaceutical Co., Ltd. Announces Treasury Stock Acquisition\uff5cNovember 2026","jir_og_description":"Kissei Pharmaceutical Co., Ltd. announces a treasury stock buyback, disclosing the acquisition cap and total amount, along with the announcement date and method. This move is part of shareholder return initiatives.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8930,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-141387","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n